Contineum Total Assets from 2010 to 2025
| CTNM Stock | 10.96 0.11 1.01% |
Total Assets | First Reported 2010-12-31 | Previous Quarter 212.8 M | Current Value 127.7 M | Quarterly Volatility 39.9 M |
Check Contineum Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Contineum Therapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 9.4 M, Interest Income of 9.4 M or Depreciation And Amortization of 221.4 K, as well as many indicators such as Price To Sales Ratio of 6.23, Dividend Yield of 0.0 or PTB Ratio of 1.5. Contineum financial statements analysis is a perfect complement when working with Contineum Therapeutics, Valuation or Volatility modules.
Contineum | Total Assets | Build AI portfolio with Contineum Stock |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Contineum Therapeutics, Correlation against competitors. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Contineum Therapeutics,. If investors know Contineum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Contineum Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Contineum Therapeutics, is measured differently than its book value, which is the value of Contineum that is recorded on the company's balance sheet. Investors also form their own opinion of Contineum Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Contineum Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Contineum Therapeutics,'s market value can be influenced by many factors that don't directly affect Contineum Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Contineum Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Contineum Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Contineum Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.